Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 11:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Albuterol Clear all
Completed Phase 4 Interventional Results available

Continuous Levalbuterol for Treatment of Status Asthmaticus in Children

NCT00124176
View directory record Official record
Conditions
Asthma
Interventions
Racemic albuterol (R+S albuterol), Levalbuterol (R albuterol)
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
6 Years to 18 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 13, 2013 · Synced Jul 23, 2026, 11:40 PM EDT
Completed Not applicable Interventional

Study of Albuterol and Oxandrolone in Patients With Facioscapulohumeral Dystrophy (FSHD)

NCT00027391
View directory record Official record
Conditions
Muscular Dystrophies
Interventions
Albuterol, Oxandrolone
Drug
Lead sponsor
FDA Office of Orphan Products Development
Federal
Eligibility
18 Years to 80 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 24, 2015 · Synced Jul 23, 2026, 11:40 PM EDT
Completed Phase 1 Interventional

Acute Bronchodilator Effect of Inhaled Albuterol Sulfate and Ipratropium Bromide in Patients With Stable COPD

NCT03480997
View directory record Official record
Conditions
COPD
Interventions
Albuterol Sulfate and Ipratropium Bromide, Albuterol Sulfate
Combination Product
Lead sponsor
Pneuma Respiratory, Inc
Industry
Eligibility
40 Years to 80 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Hickory, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 28, 2018 · Synced Jul 23, 2026, 11:40 PM EDT
Completed Phase 2 Interventional

A Study Evaluating the Effect of Inhaled PT007(AS MDI) Versus Placebo MDI and Ventolin Evohaler on Lung Function in Adult Participants With Asthma

NCT06644924
View directory record Official record
Conditions
Asthma
Interventions
Intervention: AS MDI, Intervention: Ventolin Evohaler, Intervention: Placebo matching AS MDI
Combination Product
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
22
States / cities
Encinitas, California • Lancaster, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2025 · Synced Jul 23, 2026, 11:40 PM EDT
Completed Phase 3 Interventional Results available

A 12-week Study to Compare the Efficacy and Safety of Albuterol Spiromax® Versus a Placebo in People 12 Years and Older With Persistent Asthma

NCT01424813
View directory record Official record
Conditions
Asthma
Interventions
Placebo MDPI, Albuterol MDPI
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
12 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
38
States / cities
Birmingham, Alabama • Phoenix, Arizona • Costa Mesa, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2015 · Synced Jul 23, 2026, 11:40 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Participants With Asthma

NCT02969408
View directory record Official record
Conditions
Asthma
Interventions
Albuterol Sulfate
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years and older
Enrollment
397 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
44
States / cities
Litchfield Park, Arizona • Bakersfield, California • Los Angeles, California + 37 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced Jul 23, 2026, 11:40 PM EDT
Completed Phase 2 Interventional

A Safety and Tolerability Study of Levalbuterol HFA Metered Dose Inhaler in Subjects With Asthma

NCT00684827
View directory record Official record
Conditions
Asthma
Interventions
Levalbuterol HFA MDI followed by Racemic albuterol HFA MDI, Racemic Albuterol followed by levalbuterol HFA MDI
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
12 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
4
States / cities
Encinitas, California • Los Angeles, California • North Dartmouth, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2012 · Synced Jul 23, 2026, 11:40 PM EDT
Completed Phase 3 Interventional Results available

A Phase III Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination (FDC) of Fluticasone Furoate+Umeclidinium Bromide+Vilanterol (FF/UMEC/VI) With the FDC of FF/VI in Subjects With Inadequately Controlled Asthma

NCT02924688
View directory record Official record
Conditions
Asthma
Interventions
FF/UMEC/VI (100/31.25/25) mcg, FF/UMEC/VI (100/62.5/25) mcg, FF/UMEC/VI (200/31.25/25) mcg, FF/UMEC/VI (200/62.5/25) mcg, FF/VI (100/25) mcg, FF/VI (200/25) mcg, Fluticasone/salmeterol (FSC), Albuterol/salbutamol, ELLIPTA DPI, DISKUS DPI, METERED-DOSE INHALER (MDI)
Drug · Device
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
2,436 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
99
States / cities
Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 89 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2021 · Synced Jul 23, 2026, 11:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Pre-Treatment With Cromolyn or Albuterol on Response to PUL-042 Inhalation Solution (PUL-042)

NCT02566252
View directory record Official record
Conditions
Healthy
Interventions
PUL-042 Inhalation Solution, Cromolyn Sodium, Albuterol sulfate
Drug
Lead sponsor
Pulmotect, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Aug 9, 2017 · Synced Jul 23, 2026, 11:40 PM EDT
Completed Not applicable Interventional Results available

A Comparison of Levalbuterol Plus Ipratropium With Levalbuterol Alone in the Treatment of Acute Asthma Exacerbation

NCT00583778
View directory record Official record
Conditions
Asthma
Interventions
ipratropium
Drug
Lead sponsor
MetroHealth Medical Center
Other
Eligibility
18 Years to 45 Years
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 15, 2022 · Synced Jul 23, 2026, 11:40 PM EDT
Completed Phase 2 Interventional Results available

A Safety and Tolerability Study of Arformoterol Tartrate Inhalation Solution in Pediatric Subjects

NCT00583947
View directory record Official record
Conditions
Asthma
Interventions
arformoterol, levalbuterol
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
2 Years to 11 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
14
States / cities
Beverly Hills, California • Orange, California • Savannah, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2012 · Synced Jul 23, 2026, 11:40 PM EDT
Terminated Phase 4 Interventional Results available

Comparison of Albuterol for Status Asthmaticus

NCT02966184
View directory record Official record
Conditions
Status Asthmaticus
Interventions
preservative free albuterol
Drug
Lead sponsor
Norton Healthcare
Other
Eligibility
5 Years to 17 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated May 19, 2021 · Synced Jul 23, 2026, 11:40 PM EDT
Withdrawn Phase 2Phase 3 Interventional

Nebulized Albuterol for Congestive Heart Failure Exacerbation

NCT01375361
View directory record Official record
Conditions
Congestive Heart Failure
Interventions
Albuterol, Normal Saline
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 9, 2013 · Synced Jul 23, 2026, 11:40 PM EDT
Completed Phase 1 Interventional

Albuterol in Individuals With Late Onset Pompe Disease (LOPD)

NCT01859624
View directory record Official record
Conditions
Pompe Disease
Interventions
Albuterol
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 4, 2019 · Synced Jul 23, 2026, 11:40 PM EDT
Terminated Phase 3 Interventional

4-Week Study of Efficacy, Safety and PK of Albuterol-HFA Versus Proventil-HFA in Pediatric Asthma

NCT00634517
View directory record Official record
Conditions
Asthma
Interventions
Armstrong Albuterol Sulfate Inhalation Aerosol, Albuterol Sulfate Inhalation Aerosol
Drug
Lead sponsor
Amphastar Pharmaceuticals, Inc.
Industry
Eligibility
4 Years to 11 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
8
States / cities
Long Beach, California • San Diego, California • Stockton, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2013 · Synced Jul 23, 2026, 11:40 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Functional Studies of Novel Genes Mutated in Primary Ciliary Dyskinesia II: Genotype to Phenotype

NCT04901715
View directory record Official record
Conditions
Primary Ciliary Dyskinesia
Interventions
Albuterol, Technetium99m - Sulfur Colloid (Tc99m-SC)
Drug · Diagnostic Test
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
12 Years to 90 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Jul 23, 2026, 11:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fasting Study of Albuterol Sulfate Extended-Release Tablets 8 mg and VoSpire® ER Tablets 8 mg

NCT00649779
View directory record Official record
Conditions
Healthy
Interventions
albuterol sulfate extended-release 8 mg tablets, VoSpire™ ER 8 mg tablets
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Mar 31, 2008 · Synced Jul 23, 2026, 11:40 PM EDT
Withdrawn Not applicable Interventional

Steroids Helping Albuterol Responders Exclusively

NCT00798616
View directory record Official record
Conditions
Bronchiolitis
Interventions
prednisolone or methylprednisolone, placebo
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
4 Weeks to 24 Months
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 8, 2014 · Synced Jul 23, 2026, 11:40 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy of Albuterol Administered by the Halix™ Dry Powder Inhaler in Subjects With Asthma

NCT03643874
View directory record Official record
Conditions
Asthma
Interventions
Halix albuterol 90 mcg, albuterol HFA MDI 90 mcg
Drug
Lead sponsor
Concentrx Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 29, 2019 · Synced Jul 23, 2026, 11:40 PM EDT
Completed Phase 2 Interventional

Dose Response Study of Levalbuterol in the Prevention of Exercise Induced Bronchoconstriction Compared to Racemic Albuterol in Pediatric Subjects

NCT00685347
View directory record Official record
Conditions
Asthma, Bronchoconstriction
Interventions
Levalbuterol HFA MDI, Racemic Albuterol
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
6 Years to 11 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003
U.S. locations
6
States / cities
Long Beach, California • Denver, Colorado • Englewood, Colorado + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2012 · Synced Jul 23, 2026, 11:40 PM EDT
Completed Phase 3 Interventional Results available

Albuterol HFA MDI in Pediatric Participants With Asthma

NCT00577655
View directory record Official record
Conditions
Asthma
Interventions
Albuterol, Placebo, Proventil® HFA
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
4 Years to 11 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
13
States / cities
Huntington Beach, California • Palmdale, California • Paramount, California + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 11, 2021 · Synced Jul 23, 2026, 11:40 PM EDT
Completed Phase 3 Interventional

Efficacy Study of Single-Dose Levalbuterol Tartrate HFA MDI Vs Placebo in Subjects 18 Years and Older With EIB

NCT00268723
View directory record Official record
Conditions
Exercise-induced Bronchospasm
Interventions
Levalbuterol tartrate HFA MDI, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
2
States / cities
Denver, Colorado • Burke, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 21, 2012 · Synced Jul 23, 2026, 11:40 PM EDT
Completed Phase 3 Interventional Results available

Study to Determine the Onset of Action of Indacaterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

NCT00669617
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Indacaterol, Salmeterol/fluticasone (50/500 μg), Salbutamol (200 µg), Placebo to Indacaterol, Placebo to Salmeterol/fluticasone, Placebo to salbutamol
Drug
Lead sponsor
Novartis
Industry
Eligibility
40 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
5
States / cities
Tamarac, Florida • Lafayette, Louisiana • Saint Charles, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2011 · Synced Jul 23, 2026, 11:40 PM EDT
Completed Phase 3 Interventional Results available

Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Participants With Chronic Obstructive Pulmonary Disease (COPD)

NCT03256695
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Albuterol sulfate (ABS)
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
40 Years and older
Enrollment
405 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
40
States / cities
Andalusia, Alabama • Anniston, Alabama • Mobile, Alabama + 34 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced Jul 23, 2026, 11:40 PM EDT